Vertex Pharmaceuticals Sustainability Profile
Vertex Pharmaceuticals Incorporated, commonly known as Vertex, is a leading biotechnology company headquartered in the United States. Founded in 1989, Vertex has established itself as a pioneer in the development of transformative therapies for serious diseases, particularly in the field of cystic fibrosis. With major operational regions across North America and Europe, the company focuses on innovative drug discovery and development. Vertex is renowned for its unique portfolio of cystic fibrosis treatments, including Kalydeco, Orkambi, and Trikafta, which have significantly improved the quality of life for patients. The company’s commitment to research and development has positioned it as a market leader, achieving notable milestones such as the first approved therapy for the underlying cause of cystic fibrosis. Vertex continues to drive advancements in biotechnology, solidifying its reputation as a key player in the industry.
DitchCarbon Score
How does Vertex Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vertex Pharmaceuticals's score of 50 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Vertex Pharmaceuticals's reported carbon emissions
In 2024, Vertex Pharmaceuticals reported total carbon emissions of approximately 551,647,000 kg CO2e, with significant contributions from Scope 3 emissions, which accounted for about 551,647,000 kg CO2e. Scope 1 emissions were approximately 8,976,000 kg CO2e, and Scope 2 emissions totalled about 3,930,000 kg CO2e. The combined Scope 1 and 2 emissions amounted to approximately 12,906,000 kg CO2e. In 2023, the company recorded total emissions of about 474,129,000 kg CO2e in Scope 3, with Scope 1 emissions at approximately 8,311,000 kg CO2e and Scope 2 emissions at about 4,888,000 kg CO2e, leading to a total of approximately 13,198,000 kg CO2e for Scope 1 and 2 combined. Vertex Pharmaceuticals has not publicly disclosed specific reduction targets or initiatives as part of its climate commitments. The company does not appear to have cascaded data from any parent organisation, and its emissions data is solely attributed to Vertex Pharmaceuticals Incorporated. Overall, Vertex Pharmaceuticals is actively monitoring its carbon footprint across all scopes, but further details on reduction strategies or commitments remain unspecified.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 5,957,000 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 11,304,000 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Vertex Pharmaceuticals's Industry?
How Carbon Intensive is Vertex Pharmaceuticals's Location?
Vertex Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Vertex Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
